

# Andrew Aronsohn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11871438/publications.pdf>

Version: 2024-02-01

24  
papers

762  
citations

933447

10  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1597  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, 1090-1099.e1.	1.3	487
2	Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005325.	4.7	74
3	Distributive justice and the arrival of direct-acting antivirals: Who should be first in line?. <i>Hepatology</i> , 2011, 53, 1789-1791.	7.3	29
4	Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 661-671.	2.2	26
5	Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. <i>Transplantation</i> , 2021, 105, 1285-1290.	1.0	25
6	Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. <i>Hepatology</i> , 2012, 56, 1591-1592.	7.3	24
7	Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series. <i>Topics in Antiviral Medicine</i> , 2017, 25, 110-113.	0.1	20
8	Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy. <i>Hepatology</i> , 2014, 59, 13-15.	7.3	13
9	Hepatobiliary Manifestations of Critically Ill and Postoperative Patients. <i>Clinics in Liver Disease</i> , 2011, 15, 183-197.	2.1	12
10	Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 030-036.	3.6	11
11	“Raising HOPE” Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. <i>Transplantation Direct</i> , 2021, 7, e707.	1.6	9
12	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. <i>PLoS ONE</i> , 2017, 12, e0181603.	2.5	6
13	Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. <i>Hepatology</i> , 2014, 59, 1688-1691.	7.3	5
14	Overcoming injustice: A roadmap to improve access to hepatitis C virus therapy for our medicaid patients. <i>Hepatology</i> , 2017, 65, 1735-1740.	7.3	5
15	Is the HCV Pipeline Heading in the Right Direction?. <i>Gastroenterology</i> , 2013, 144, 482-485.	1.3	4
16	Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents. <i>Hepatology</i> , 2018, 68, 2004-2007.	7.3	4
17	Calciphylaxis in end-stage liver and renal disease patients before and after transplant. <i>Clinical Transplantation</i> , 2018, 32, e13272.	1.6	2
18	Elimination of Hepatitis B and C Virus Infections. <i>Gastroenterology and Hepatology</i> , 2018, 14, 240-243.	0.1	2

#	ARTICLE	IF	CITATIONS
19	The long-term horizon: Patients who will remain untreated in the era of triple therapy. <i>Clinical Liver Disease</i> , 2012, 1, 20-23.	2.1	1
20	HCV Therapy: Treat now or wait?. <i>Current Hepatitis Reports</i> , 2013, 12, 7-12.	0.3	1
21	A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy. <i>ACG Case Reports Journal</i> , 2015, 2, 42-44.	0.4	1
22	You Canâ€™t Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2015-2019.	4.4	1
23	HCV Eradication: Implications for Disease Resolution. <i>Current Hepatitis Reports</i> , 2011, 10, 27-32.	0.3	0
24	The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System. <i>Current Hepatology Reports</i> , 2017, 16, 192-197.	0.9	0